Persistence of SARS-CoV-2: a new paradigm of COVID-19 management.


Alhusseini LB(1), Yassen LT(2), Kouhsari E(3)(4), Al Marjani MF(5).
Author information:
(1)Department of Ecology, College of Science, Kufa University, Najaf, Iraq.
(2)Department of Medical Laboratory Techniques, Osoul Aldeen University College, Baghdad, Iraq.
(3)Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
(4)Department of Laboratory Sciences, Faculty of Paramedicine, Golestan University of Medical Sciences, Gorgan, Iran.
(5)Department of Biology, College of Science, Mustansiriyah University, Baghdad, Iraq.


Full attention must be given to the follow-up of patients recovered from Coronavirus disease 2019, which developed in Wuhan, China in December 2019. Among the most serious issues since the emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 has been whether those who had it can experience a second episode of infection and what that implies for immunity. The earlier studies on COVID-19 disease focused primarily on the epidemiological, clinical, and radiological characteristics of patients with CO-VID-19. However, conclusions of these studies still require to be warranted by more careful design, larger sample size and statistically well structured studies. COVID-19 is an under-studied infection, and several aspects of viral transmission and clinical progress remain at present unclear. There is a concern about the persistence of SARS-CoV-2 on various surfaces and in the respiratory system of patients who have survi-ved. One of the most concerning issues since the emergence of the SARS-CoV-2 is persistence in patients and whether patients can be re-infected. After hospital discharge, recovered patients were reported to have positive SARS-CoV-2 test in China, Japan, and South Korea. In addition to the persistence of the virus, SARS-CoV-2 re-infection may occur in survivors. In this paper, we focused on the evidence of persistence and re-infection of SARS-CoV-2.